Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patients

29 Nov 2021

Abstract excerpt

MammaPrint® (MP) is a 70-gene signature that stratifies early-stage breast cancer patients into low- and high risk of distant relapse. Further stratification of MP risk results identifies four risk subgroups, ultra-low (UL), low, high 1, and high 2, with specific prognostic and predictive outcomes. BluePrint® (BP) is an 80-gene signature that classifies breast tumors as basal, luminal, or HER2 molecular subtype....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Cancer Treatment Studies
Share to Cancer Cells and Metastasis
Share to Ferroptosis and cancer prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34841595
DOI: 10.1002/gcc.23014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patientsPMID 34841595Read ↗

Biological Functions of the Genes in the Mammaprint Breast Cancer Profile Reflect the Hallmarks of CancerSemantic proximity Read ↗

Clinical and Molecular Characteristics of ER-Positive Breast Cancer Tumors Identified as Ultralow Risk by the 70-Gene Signature in a Randomized Clinical TrialSemantic proximity Read ↗

Minireview: Basal-Like Breast Cancer: From Molecular Profiles to Targeted TherapiesSemantic proximity Read ↗

Clinical and molecular characteristics of estrogen receptor‐positive ultralow risk breast cancer tumors identified by the 70‐gene signatureSemantic proximity Read ↗

Whole transcriptome analysis reveal MammaPrint and BluePrint-associated gene expression patterns with early lymph node metastasis in early-stage breast cancerSemantic proximity Read ↗

Cancer Hallmarks, Biomarkers and Breast Cancer Molecular SubtypesSemantic proximity Read ↗

Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific TreatmentsSemantic proximity Read ↗

High concordance of 70-gene recurrence risk signature and 80-gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early-stage breast cancerSemantic proximity Read ↗

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.Semantic proximity Read ↗

Basal-like breast cancer: molecular profiles, clinical features and survival outcomesSemantic proximity Read ↗

Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment StrategiesSemantic proximity Read ↗

Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.